Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.

The Journal of Clinical Endocrinology and Metabolism
Tilman D RachnerLorenz C Hofbauer

Abstract

Aromatase inhibitors have become a mainstay in the adjuvant treatment regimen in postmenopausal women with hormone receptor-positive breast cancer. While many of these patients have an excellent long-term prognosis, adverse effects on bone represent an emerging complication of aromatase inhibitor treatment, resulting in substantial bone loss and fragility fractures. Treatment approaches to prevent aromatase inhibitor-induced bone loss typically consist of an antiresorptive approach with bisphosphonates or the RANKL antibody denosumab. However, different guidelines vary with respect to treatment thresholds, duration, and dosing. The choice of antiresorptive regime is further complicated by comorbidities and potential disease-modifying effects of individual agents. This review summarizes the evidence of how aromatase inhibitors affect bone health and provides an update of clinical approaches to preserve bone strength in affected women. (J Clin Endocrinol Metab XX: 0-0, 2020).

References

Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J PowlesS Ashley
Jun 28, 2000·Proceedings of the National Academy of Sciences of the United States of America·N K ShevdeJ W Pike
Jan 12, 2002·JAMA : the Journal of the American Medical Association·Steven R CummingsUNKNOWN Multiple Outcomes of Raloxifene Evaluation (MORE) Trial
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen GeislerPer Eystein Lønning
Feb 1, 2002·The New England Journal of Medicine·Christian J GruberJohannes C Huber
Apr 19, 2002·The Oncologist·David S Goodsell
Aug 21, 2003·Breast Cancer Research : BCR·Ruth C Travis, Timothy J Key
Nov 19, 2003·The Journal of Steroid Biochemistry and Molecular Biology·E R Simpson
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Jul 7, 2005·The Journal of Clinical Endocrinology and Metabolism·Sundeep KhoslaL Joseph Melton
Nov 9, 2007·Molecular Cancer Therapeutics·Eric A AriaziV Craig Jordan
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard EastellGlen Clack
May 2, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HadjiM Tubiana-Hulin
Jul 11, 2008·The American Journal of Clinical Nutrition·Marian L NeuhouserRachel Ballard-Barbash
Aug 23, 2008·The Lancet Oncology·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgiana K EllisSusie Jun
Feb 14, 2009·The New England Journal of Medicine·Michael GnantC Marth
May 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M RabaglioUNKNOWN BIG 1-98 Collaborative and International Breast Cancer Study Groups
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettRichard Peto
Aug 24, 2010·Breast Cancer Research and Treatment·Robert E ColemanLucy S Kilburn
Oct 12, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R EastellR E Coleman
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Nov 13, 2010·The Breast Journal·Nicola NapoliReina Armamento-Villareal
Apr 1, 2011·Lancet·Tilman D RachnerLorenz C Hofbauer
Feb 2, 2012·International Journal of Breast Cancer·Sudipa Saha Roy, Ratna K Vadlamudi
Oct 11, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ColemanN Bundred
Jan 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul E GossLois E Shepherd
Sep 6, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Julie R GralowCatherine H Van Poznak
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Elizabeth Folkerd, Mitch Dowsett
May 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ColemanUNKNOWN ESMO Guidelines Working Group
Mar 12, 2015·Breast Care·Christoph Domschke, Florian Schuetz
Apr 23, 2015·The Journal of Endocrinology·Tony M Plant
Jan 1, 2014·Breast Cancer Research : BCR·Carolyn L SmithSebastian Mirkin
Jun 5, 2015·Lancet·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

❮ Previous
Next ❯

Citations

Apr 21, 2021·Nature Reviews. Clinical Oncology·Lorenz C HofbauerKlaus Pantel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Opinion in Obstetrics & Gynecology
Nigel J Bundred
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Amy Jo Chien, Paul E Goss
Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Yasuhiro MikiHironobu Sasano
The Journal of Steroid Biochemistry and Molecular Biology
Richard Eastell
© 2021 Meta ULC. All rights reserved